Insider Transactions in Q2 2023 at Replimune Group, Inc. (REPL)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 13
2023
|
Sushil Patel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,698
-1.85%
|
$131,054
$23.78 P/Share
|
|
Jun 13
2023
|
Tanya Lewis Chief Dev. Op. Officer |
SELL
Open market or private sale
|
Direct |
12,860
-4.36%
|
$295,780
$23.78 P/Share
|
|
May 16
2023
|
Robert Coffin Director |
SELL
Open market or private sale
|
Direct |
7,861
-0.43%
|
$141,498
$18.05 P/Share
|
|
May 16
2023
|
Sushil Patel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,575
-9.15%
|
$280,350
$18.05 P/Share
|
|
May 16
2023
|
Philip Astley Sparke Executive Chairman |
SELL
Open market or private sale
|
Direct |
17,902
-1.16%
|
$322,236
$18.05 P/Share
|
|
May 16
2023
|
Pamela Esposito Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,966
-2.21%
|
$107,388
$18.05 P/Share
|
|
May 16
2023
|
Konstantinos Xynos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
771
-0.64%
|
$13,878
$18.05 P/Share
|
|
May 16
2023
|
Jean M. Franchi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,351
-8.1%
|
$204,318
$18.05 P/Share
|
|
May 16
2023
|
Colin Love Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,775
-1.34%
|
$193,950
$18.05 P/Share
|
|
May 16
2023
|
Tanya Lewis Chief Dev. Op. Officer |
SELL
Open market or private sale
|
Direct |
12,207
-7.61%
|
$219,726
$18.05 P/Share
|
|
Apr 01
2023
|
Philip Astley Sparke Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
142,100
+8.43%
|
-
|
|
Apr 01
2023
|
Robert Coffin Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+2.39%
|
-
|
|
Apr 01
2023
|
Sushil Patel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+19.03%
|
-
|
|
Apr 01
2023
|
Tanya Lewis Chief Dev. Op. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+19.96%
|
-
|
|
Apr 01
2023
|
Colin Love Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+4.73%
|
-
|
|
Apr 01
2023
|
Jean M. Franchi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+24.31%
|
-
|
|
Apr 01
2023
|
Konstantinos Xynos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+29.27%
|
-
|
|
Apr 01
2023
|
Pamela Esposito Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+12.93%
|
-
|